Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T
Department of Molecular Immunology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Cancer. 1996 Apr 15;77(8):1501-9. doi: 10.1002/(SICI)1097-0142(19960415)77:8<1501::AID-CNCR12>3.0.CO;2-3.
A large number of monoclonal antibodies (MoAbs) against human tumor cells have been generated and it has been shown that these MoAbs are useful tools in the diagnosis and treatment of cancer patients, as well as in the basic investigation of the oncogenesis and characterization of cancer cells.
The 22-1-1 MoAb was established by cell fusion between mouse myeloma cells and spleen cells derived from mice immunized with the human uterine cervical adenocarcinoma cell line, SiSo. The tissue distribution and biologic characteristics of the 22-1-1 antigen (Ag) were examined.
The 22-1-1 Ag was distinct from the known tumor-associated antigens such as YH 206, GA 733, CA 125, carcinoembryonic antigen, and sialyl Le(x) molecules in an expression pattern in human tumor cell lines. An immunohistochemical study revealed that 22-1-1 Ag was expressed in 87.5% of uterine cervical adenocarcinomas, 66% of uterine endometrial adenocarcinomas, and 58.8% of ovarian carcinomas. Moreover, 22-1-1 Ag was detected in 87.7% of uterine cervical squamous cell carcinomas; however, it was not detected in 87.7% of uterine cervical or ovarian tissues, except in uterine endometrial glands, in which its expression was observed at low levels. The 22-1-1 Ag was secreted into cell culture supernatant fluids and was also detected in the vaginal discharges of uterine cervical carcinoma patients. The antigenic epitope of 22-1-1 Ag was shown to be a protein with a molecular weight of 78 kilodaltons using sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis.
The 22-1-1 MoAb reactive to a novel tumor-associated antigen was generated. This Ag was expressed in cancer cells derived mainly from the uterus and ovary. Moreover, 22-1-1 Ag was associated in the vaginal discharges of uterine cervical carcinoma patients. 22-1-1 MoAb is a potential tool for the study of oncogenesis and the management of cancer patients.
已经产生了大量针对人类肿瘤细胞的单克隆抗体（MoAb），并且已经证明这些单克隆抗体是癌症患者诊断和治疗以及癌细胞发生机制基础研究和特征表征的有用工具。
通过小鼠骨髓瘤细胞与用人类子宫颈腺癌细胞系SiSo免疫的小鼠的脾细胞进行细胞融合建立了22-1-1单克隆抗体。检查了22-1-1抗原（Ag）的组织分布和生物学特性。
在人类肿瘤细胞系的表达模式中，22-1-1抗原与已知的肿瘤相关抗原如YH 206、GA 733、CA 125、癌胚抗原和唾液酸化Le(x)分子不同。免疫组织化学研究显示，22-1-1抗原在87.5%的子宫颈腺癌、66%的子宫内膜腺癌和58.8%的卵巢癌中表达。此外，在87.7%的子宫颈鳞状细胞癌中检测到22-1-1抗原；然而，在87.7%的子宫颈或卵巢组织中未检测到，除了子宫内膜腺，在其中观察到其低水平表达。22-1-1抗原分泌到细胞培养上清液中，并且在子宫颈癌患者的阴道分泌物中也被检测到。使用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳分析显示，22-1-1抗原的抗原表位是一种分子量为78千道尔顿的蛋白质。
产生了对一种新型肿瘤相关抗原有反应的22-1-1单克隆抗体。这种抗原主要在源自子宫和卵巢的癌细胞中表达。此外，22-1-1抗原与子宫颈癌患者的阴道分泌物有关。22-1-1单克隆抗体是肿瘤发生机制研究和癌症患者管理的潜在工具。
